N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment.
| Autor: | Micheletto C; Respiratory Unit, Cardio-Thoracic Department, Integrated University Hospital of Verona, Verona, Italy. mcpachecog@utp.edu.co., Izquierdo JL, Avdeev SN, Rada Escobar RA, Pacheco Gallego MC |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2022 Jul; Vol. 26 (13), pp. 4872-4880. |
| DOI: | 10.26355/eurrev_202207_29212 |
| Abstrakt: | Objective: Growing interest is directed to the outcomes of COVID-19 in survivors, both in the convalescent period and in the long-term, which are responsible for morbidity and quality of life deterioration. This article aims to describe the mechanisms supporting the possible use of NAC as an adjuvant treatment for post-COVID-19 pulmonary fibrosis. Materials and Methods: A search was performed in PubMed/MEDLINE. Results: Interstitial changes have been observed in the CT scan of COVID-19 pneumonia. In patients with respiratory outcomes in the post-COVID-19 stage, glutathione (GSH) deficiency was found and interpreted as a reaction to the inflammatory cascade caused by the viral infection, while the pathophysiological process of pulmonary fibrosis involves numerous cytokines, such as TGF-β, TNF-α, IL-1, PDGF and VEGF. NAC has a good tolerability profile, is easily administered orally and inexpensively, and has antioxidant and anti-inflammatory effects that may target the pathophysiologic mechanisms involved in pulmonary fibrosis. It may revert GSH deficiency, exerts direct and indirect antioxidant activity, anti-inflammatory activity and improves immune T-cell response. Conclusions: The mechanism of action of NAC suggests a role in the treatment of pulmonary fibrosis induced by COVID-19. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|